Walgreens Boots Alliance with cautious analyst tone, shares trade steadily on the Nasdaq

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 20:55.

Walgreens Boots Alliance (US9314271019) remains a closely watched name on the Nasdaq as investors weigh a mixed analyst backdrop and ongoing margin headwinds in its retail and pharmacy operations, according to recent Wall Street commentary. MarketWatch data on the Walgreens Boots Alliance shares The focus today is squarely on consensus estimates and rating distribution rather than fresh corporate news.

What recent analyst notes show

Coverage of Walgreens Boots Alliance is dominated by large US houses that point to pressured profitability in bricks-and-mortar pharmacy retail and a still-evolving turnaround plan. Reuters analysis of Walgreens Boots Alliance margin pressure Several firms highlight that comparable script growth is modest, while reimbursement dynamics and generic deflation constrain gross margins in core US pharmacy.

Consensus compiled on major data platforms indicates that a marked share of analysts rate Walgreens Boots Alliance at Hold or equivalent, with fewer Buy recommendations than seen in large-cap peers such as CVS Health or Walmart’s health-related activities. MarketScreener consensus overview for Walgreens Boots Alliance Average 12-month price targets sit only moderately above the current quotation, underlining a cautious stance on near-term upside.

Rating distribution and earnings expectations

The current consensus picture for Walgreens Boots Alliance shows a split between Buy, Hold and Sell ratings, with neutral recommendations forming the largest block. finanzen.net analyst rating summary for Walgreens Boots Alliance Several analysts cite execution risk in the transformation program and uncertainty about traffic trends in US retail pharmacies as reasons to remain cautious.

On the earnings side, Wall Street models subdued adjusted earnings-per-share growth over the next fiscal year, reflecting continued investments in health services, store remodeling and technology, as well as competitive pressure from online and omnichannel players. Nasdaq earnings expectations for Walgreens Boots Alliance The next quarterly update will be closely watched for signs that cost savings and portfolio adjustments can offset reimbursement and wage pressures.

The retail pharmacy business behind the stock

Walgreens Boots Alliance generates most of its revenue from dispensing prescription medications, retail pharmacy sales and health and wellness products across its extensive store network in the United States, the United Kingdom and other markets. Walgreens Boots Alliance business overview The company also operates international wholesale distribution through Alliance Healthcare and increasingly focuses on health services such as primary care partnerships.

Where the Walgreens Boots Alliance shares trade today

The Walgreens Boots Alliance shares (US9314271019) most recently traded on the Nasdaq at around 17 dollars in US trading, with a corresponding market capitalization in the mid-teens billion-dollar range, based on public quote data. Nasdaq price and market cap data for Walgreens Boots Alliance

This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell any security, or a solicitation of any kind. All data are based on sources believed to be reliable but cannot be guaranteed; investors should perform their own research and consider their individual financial situation before making investment decisions.